Gastrooesophageal reflux disease

Best Practice and Research in Clinical Gastroenterology

Volumn 21, Issue 4, 2007, Pages 609-631

  Richter, Joel E ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Fundoplication; Gastrooesophageal reflux disease; pH testing; Proton pump inhibitors; Upper endoscopy

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; ANTACID AGENT; BACLOFEN; BULKING AGENT; CANNABINOID; CHOLECYSTOKININ RECEPTOR STIMULATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; ENTERYX; ESOMEPRAZOLE; GAVISCON; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; MORPHINE; NITRIC OXIDE SYNTHASE INHIBITOR; NON PRESCRIPTION DRUG; OMEPRAZOLE; PANTOPRAZOLE; PLACEBO; POTASSIUM COMPETITIVE ACID BLOCKER; PROTON PUMP INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; BARRETT ESOPHAGUS; CALCIUM METABOLISM; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; DIAPHRAGM; DROWSINESS; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; ENDOSCOPIC THERAPY; ESOPHAGOSCOPY; ESOPHAGUS MANOMETRY; ESOPHAGUS PH; ESOPHAGUS STRICTURE; GASTROESOPHAGEAL REFLUX; HEARTBURN; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HIATUS HERNIA; HUMAN; INTESTINE INFECTION; LAPAROSCOPIC SURGERY; LIFESTYLE MODIFICATION; LOWER ESOPHAGUS SPHINCTER; MEDICAL RESEARCH; NAUSEA; OBESITY; PH MEASUREMENT; PREVALENCE; RISK FACTOR; SEIZURE; SENSITIVITY AND SPECIFICITY; SIDE EFFECT; SINGLE DRUG DOSE; SMOOTH MUSCLE RELAXATION; STOMACH POLYP; SYMPTOMATOLOGY;

ESOPHAGEAL SPHINCTER, LOWER; GASTROESOPHAGEAL REFLUX; HUMANS; RISK FACTORS;

EID: 34447536740     PISSN: 15216918     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bpg.2007.03.003     Document Type: Article

References (102)

1. Shaheen N.J., Hansen R.A., Morgan D.R., et al. The burden of gastrointestinal and liver diseases, 2006. Am J Gastroenterol 101 (2006) 2128-2138
2. Vakil N., Van Zanten S.V., Kahrilas P., et al. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence based consensus. Am J Gastroenterol 101 (2006) 1900-1920
3. Dent J., El Serag H.B., Wallander M.A., et al. Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut 54 (2005) 710-771
4. Ronkainen J., Aro P., Storskrubb T., et al. High prevalence of gastroesophageal reflux symptoms and esophagitis with or without symptoms in the general adult Swedish population: a Kalixandra study report. Scand J Gastroenterol 40 (2005) 275-285
5. Locke III G.R., Talley N.J., Fett S.L., et al. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmstead County, Minnesota. Gastroenterology 112 (1997) 1448-1456
6. Johnson D.A., and Fennerty M.B. Heartburn severity underestimates erosive esophagitis severity in elderly patients with gastroesophageal reflux disease. Gastroenterology 126 (2004) 660-664
7. Ford A.C., Forman D., Reynolds P.D., et al. Ethnicity, gender and socioeconomic status as risk factors for esophagitis and Barrett's esophagus. Am J Epidemiol 162 (2005) 454-460
8. Howard H., Abraham N.S., and El-Serag H.B. Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Ann Intern Med 143 (2005) 199-211
9. Jacobson B.C., Somers S.C., Fuchs C.S., et al. Body-mass index and symptoms of gastroesophageal reflux in women. NEJM 354 (2006) 1340-1348
10. Corley D.A., and Kubo A. Body mass index and gastroesophageal reflux disease: a systematic review and meta-analysis. Am J Gastroenterol 108 (2006) 2619-2628
11. El Serag H.B., and Sonnenberg A.P. Opposing time trends of peptic ulcer and reflux disease. Gut 43 (1998) 327-333
12. Raghunath A., Hungin A.P., Woolf D., et al. Prevalence of Helicobacter pylori in patients with gastro-esophageal reflux disease: a systematic review. BMJ 326 (2003) 737-740
13. Labenz J., and Malfertheiner P. Helicobacter pylori in gastro-oesophageal reflux disease: causal agent, independent or protective factor?. Gut 41 (1997) 277-280
14. Cameron A.J., Lagergren J., Henriksson C., et al. Gastroesophageal reflux disease in monozygotic and dizygotic twins. Gastroenterology 122 (2002) 55-59
15. Mohammed I., Cherkas L.F., Riley S.A., et al. Genetic influences in gastro-oesophageal reflux disease: a twin study. Gut 52 (2003) 1085-1089
16. Hu F.Z., Preston R.A., Post J.C., et al. Mapping of a gene for severe pediatric reflux disease on chromosome 13q14. JAMA 284 (2000) 325-330
17. Dodds W.J., Dent J., Hogan W.J., et al. Mechanisms of gastroesophageal reflux in patients with reflux esophagitis. NEJM 307 (1982) 1547-1552
18. Mittal R.K., and Balahan D.H. The esophagogastric junction. NEJM 336 (1997) 924-930
19. Mittal R.K., Holloway R.H., Penagini R., et al. Transient lower esophageal sphincter relaxation. Gastroenterology 109 (1995) 601-609
20. Sifrim D., and Holloway R. Transient lower esophageal sphincter relaxation: how many or how harmful?. Am J Gastroenterol 96 (2001) 2529-2532
21. Pandolfino J., Zhang Q., Ghosh S., et al. Transient lower esophageal sphincter relaxation and reflux: mechanistic analysis using concurrent fluoroscopy and high-resolution manometry. Gastroenterology 131 (2006) 1725-1733
22. Dent J., Holloway R.H., Toouli J., et al. Mechanisms of lower esophageal sphincter incompetence in patients with symptomatic gastroesophageal reflux. Gut 29 (1988) 1020-1026
23. Mittal R.K., Lange R.C., and McCallum R.W. Identification and mechanism of delayed esophageal clearance in subjects with hiatus hernia. Gastroenterology 92 (1987) 130-136
24. Bredenoord A.J., Weusten B.L.A.M., Timmer R., et al. Intermittent spatial separation of diaphragm and lower esophageal sphincter favors acidic and weakly acidic reflux. Gastroenterology 125 (2006) 1018-1023
25. Pandolfino J.E., Shi G., Trueworthy B., et al. Esophagogastric junction opening during relaxation distinguishes non-hernia reflux patients, hernia patients and normal subjects. Gastroenterology 125 (2003) 1018-1023
26. Helms J.F., Dodds W.J., Pek L.R., et al. Effect of esophageal emptying and saliva on clearance of acid from the esophagus. NEJM 310 (1984) 284-289
27. Kahrilas P.J., Dodds W.J., Hogan W.J., et al. Esophageal peristaltic dysfunction in peptic esophagitis. Gastroenterol 91 (1986) 897-902
28. Orlando R.C., Bryson J.C., and Powell D.W. Mechanisms of H+ injury in rabbit esophageal epithelium. Am J Physiol 246 (1984) A718-A723
29. Fletcher J., Wirz A., Henry E., et al. Studies of acid exposure immediately above the gastroesophageal squamocolumnar junction: evidence for short segment reflux. Gut 53 (2004) 168-172
30. Vaezi M.F., and Richter J.E. Role of acid and duodenogastroesophageal reflux in gastroesophageal reflux disease. Gastroenterol 111 (1996) 1192-1199
31. Barlow W.J., and Orlando R.C. The pathogenesis of heartburn in non-erosive disease: a unifying hypothesis. Gastroenterol 128 (2005) 771-778
32. Carlsson R., Dent J., Bolling-Sternevold F., et al. The usefulness of a structured questionnaire in the assessment of symptomatic gastroesophageal reflux disease. Scand J Gastroenterol 33 (1998) 1023-1027
33. Shaker R., Castell D.O., Schoenfeld P.S., et al. Nighttime heartburn is an under-appreciated clinical problem that impacts sleep and daytime function: the results of a Gallup survey conducted on behalf of the American Gastroenterological Association. Am J Gastroenterol 98 (2003) 1487-1493
34. Helm J.E., Dodds W.J., Hogan W.J., et al. Acid neutralizing capacity of human saliva. Gastroenterol 83 (1987) 69-75
35. Moayyedi P., Talley N.J., Fennerty M.B., et al. Can the clinical history distinguish between organic and functional dyspepsia?. JAMA 295 (2006) 1566-1576
36. Johnson D.A., Winters C., Spurling T.J., et al. Esophageal acid sensitivity in Barrett's esophagus. J Clin Gastroenterol 9 (1987) 23-27
37. Richter J.E. Diagnostic tests for gastroesophageal reflux disease. Am J Med Sci 326 (2003) 300-309
38. Richter J.E. Severe reflux esophagitis. Gastrointest Endosc Clin North Am 4 (1994) 677-698
39. Nayer D.W., and Vaezi M.F. Classification of esophagitis: who needs it?. GI Endosc 60 (2004) 253-257
40. Lundell L.R., Dent J., Bennett J.R., et al. Endoscopic assessment of oesophagitis: clinical and functional correlation and further validation of the Los Angeles classification. Gut 45 (1999) 172-180
41. Labenz J., Nocon M., Lind T., et al. Prospective follow-up from the ProGERD study suggests that GERD is not a categorical disease. Am J Gastroenterol 101 (2006) 2457-2462
42. Wo J.M., Mendez C., Harrell S., et al. Clincal impact of upper endoscopy in the management of patients with gastroesophageal reflux disease. Am J Gastroenterol 99 (2004) 2311-2316
43. DeVault K.R., and Castell D.O. American College of Gastroenterology updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 100 (2005) 190-200
44. Riddell R.H. The biopsy diagnosis of gastroesophageal reflux disease, "carditis," and Barrett's esophagus, and sequelae of therapy. Am J Surgical Pathol 20 Suppl 1 (1996) 531-550
45. Wiener G.J., Morgan T.M., Copper J.B., et al. Ambulatory 24-hour esophageal pH monitoring: reproducibility and variability of pH parameters. Dig Dis Sci 33 (1988) 1127-1133
46. Kahrilas P.J., and Quigley E.M.M. Clinical esophageal pH recording: a technical review for practice guideline development. Gastroenterol 110 (1996) 1982-1986
47. Pandolfino J.E., Richter J.E., Ours T., et al. Ambulatory esophageal pH monitoring using a wireless system. Am J Gastroenterol 94 (2003) 740-747
48. Prakash C., and Clouse R.E. Value of extended recording time with wireless pH monitoring in evaluating gastroesophageal reflux disease. Clin Gastroenterol Hepatol 3 (2005) 329-334
49. US Food and Drug Administration, and Center for Devices and Radiologic Health. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfMAUDE/search.cfm
50. Bredenoord A.J., Tutuian R., Smout A.J.P.M., et al. Technology review: esophageal impedance monitoring. Am J Gastroenterol 102 (2007) 187-194
51. Zerbid F., Roman S., Ropert A., et al. Esophageal pH-impedance monitoring and symptom analysis in GERD: a study in patients off and on therapy. Am J Gastroenterol 101 (2006) 1956-1963
52. Mainie I., Tutuian R., Shay S., et al. Acid and non-acid reflux in patients with persistent symptoms despite acid suppressive therapy. A multicenter study using combined ambulatory impedance-pH monitoring. Gut 55 (2006) 1398-1402
53. Sifrim D., Dupont L., Blondeau K., et al. Weakly acidic reflux in patients with chronic unexplained cough during 24 h pressure, pH and impedance monitoring. Gut 54 (2005) 449-454
54. Oleynikov D., Eubanks T.R., Oelschlager B.K., et al. Total fundoplication is the operation of choice for patients with gastroesophageal reflux and defective peristalsis. Surg Endosc 16 (2002) 909-916
55. Tutuian R., and Castell D.O. Classification of the esophageal function defect in patients with manometric ineffective esophageal motility: studies using combined impedance-manometry. Gastroenterology 2 (2004) 230-239
56. Numans M.E., Lau J., deWit N.J., et al. Short-term treatment with PPIs as a test for gastroesophageal reflux disease: a meta-analysis of diagnostic test characteristics. Ann Intern Med 140 (2004) 518-527
57. Fass R., and Ofman J.J. Gastroesophageal reflux disease - should we adopt a new conceptual framework?. Am J Gastroenterol 97 (2002) 1901-1909
58. Richter J.E. Peptic strictures of the esophagus. Gastroenterol Clin North Am 28 (1999) 875-892
59. Marshall J.P., Kretchman J.M., and Kiaz-Arias A.A. Gastroesophageal reflux as a pathogenic factor in the development of symptomatic lower esophageal rings. Arch Intern Med 150 (1990) 1669-1672
60. Riley S.A., and Attwood S.E.A. Guidelines on the use of esophageal dilatation in clinical practice. Gut 55 (2004) 1-7
61. Dakkak M., Hoare R.C., Maslin S.C., et al. Oesophagitis is as important as oesophageal stricture diameter in determining dysphagia. Gut 34 (1993) 152-157
62. Sharma P., Dent J., Armstrong D., et al. The development and validation of an endoscopic grading system for Barrett's esophagus: the Prague C&M criteria. Gastroenterology 131 (2006) 1392-1399
63. Hanna S., Rastogi A., Weston A.P., et al. Detection of Barrett's esophagus after endoscopic healing of erosive esophagitis. Am J Gastroenterol 101 (2006) 1416-1420
64. Shaheen N., and Ransohoff N. Gastroesophageal reflux Barrett's esophagus and esophageal cancer: scientific review. JAMA 287 (2002) 1972-1981
65. Lagergren J., Bergstrom R., Lindgren A., et al. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. NEJM 340 (1999) 825-831
66. Sharma P., McQuaid K., Dent J., et al. A critical review of the diagnosis and management of Barrett's esophagram: the AGA Chicago workshop. Gastroenterology 127 (2004) 310-330
67. Pallone F., and Galmiche J.P. Barrett's oesophagus and oesophageal adenocarcinoma. Gut 54 Suppl 1 (2005) 1-42
68. Richter J.E. Ear, nose and throat and respiratory manifestations of gastro-oesophageal reflux disease: an increasing conundrum. Eur J Gastroenterol Hepatol 16 (2004) 837-845
69. Hewson E.G., Sinclair J.W., Dalton C.B., et al. Twenty-four hour esophageal pH monitoring. The most useful test for evaluating non-cardiac chest pain. Am J Med 90 (1991) 576-582
70. Balaban D., Yamamoto Y., Liu J., et al. Sustained esophageal contraction: a marker of esophageal chest pain identified by intraluminal ultrasonography. Gastroenterology 116 (1999) 29-35
71. Kaltenback T., Crockett S., and Gerson L.B. Are lifestyle measures effective in patients with gastroesophageal reflux disease? An evidence-based approach. Arch Intern Med 166 (2006) 965-971
72. Moayyedi P., and Talley N. Gastroesophageal reflux disease. Lancet 367 (2006) 2086-2100
73. 2RAs and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev 3 (2004) CD002095
74. Donnellan C., Sharma N., Preston C., et al. Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease. Cochrane Database Syst Rev 3 (2004) CD003245
75. Gralnek I.M., Dulai G.S., Fennerty M.B., et al. Esomeprazole versus other proton pump inhibitors in erosive esophagitis: a meta-analysis of randomized clinical trials. Clin Gastroenterol Hepatol 4 (2006) 1452-1458
76. Guda N.M., and Vakil N. Proton pump inhibitors and the time trends for esophageal dilatation. Am J Gastroenterol 99 (2004) 797-800
77. Sgouros S.N., Vlachogiannakos J., Karamanolis G., et al. Long-term acid suppression therapy may prevent the relapse of lower esophageal (Schatzki's) rings: a prospective, randomized, placebo-controlled study. Am J Gastroenterol 100 (2005) 1929-1934
78. Cremmini F., Wise J., Moayyedi P., et al. Diagnostic and therapeutic use of proton pump inhibitors in non-cardiac chest pain: a meta-analysis. Am J Gastroenterol 100 (2005) 1226-1232
79. Wang W.H., Huang J.Q., Zheng G.K., et al. Is proton pump inhibitor testing an effective approach to diagnose gastroesophageal reflux disease in patients with non-cardiac chest pain? A meta-analysis. Arch Intern Med 165 (2005) 1222-1228
80. Chang A.B., Lasserson T.J., Gaffney J., et al. Gastroesophageal reflux disease for prolonged non-specific cough in children and adults. Cochrane Database Syst Rev 2 (2005) CD004823
81. Gibson P.G., Henry R.I., and Coughlan J.L. Gastro-oesophageal reflux treatment for adults and children. Cochrane Database Syst Rev 1 (2003) CD001496
82. Qadeer M.A., Philips C.O., Lopez A.R., et al. Proton pump inhibitor therapy suspected GERD-related chronic laryngitis: a meta-analysis of randomized controlled trials. Am J Gastroenterol 101 (2006) 2646-2654
83. Johnson D.A., Orr W.C., Crawley J.A., et al. Effect of esomeprazole on nighttime heartburn and sleep quality in patients with GERD: a randomized, placebo-controlled trial. Am J Gastroenterol 100 (2005) 1914-1922
84. Barrison A.F., Jarke L.A., Weinberg M.D., et al. Patterns of proton pump inhibitors in clinical practice. Am J Med 111 (2001) 469-473
85. Fass R., Sontag S.J., Traxler B., et al. Treatment of patients with persistent heartburn symtoms: a double-blind randomized trial. Clin Gastroenterol Hepatol 4 (2006) 50-56
86. Martinez S.D., Malagon I.B., Garewal H.S., et al. Non-erosive reflux disease, acid reflux and symptom pattern. Aliment Pharmacol Ther 17 (2003) 537-545
87. Richter J.E. The patient with refractory gastroesophageal reflux disease. Dis Esophagus 19 (2006) 443-447
88. Jalving M., Koornstra J.J., Wesseling J., et al. Increased risk of fundic gland polyps during long-term proton pump inhibitor therapy. Aliment Pharmacol Ther 24 (2006) 1341-1348
89. Laheij R.J.F., Sturkenboom M.C.J.M., Hassing R.J., et al. Risk of community-acquired pneumonia and use of gastric acid-suppression drugs. JAMA 292 (2004) 1955-1960
90. Leonard J, Marshall JK, Moayyedi P. Systemic review of the risk of enteric infections in patients taking acid suppression. Am J Gastroenterology, in press.
91. Yang Y.X., Lewis J.D., Epstein S., et al. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 296 (2006) 2947-2953
92. Richter J.E. New investigational therapies for gastroesophageal reflux disease. Thorac Surg Clin 15 (2005) 377-384
93. Ciccaglione A.F., and Marzio L. Effect of acute and chronic administration of the GABA B agonist baclofen on 24 hr pH-metry and symptoms in control subjects and patients with gastro-oesophageal reflux disease. Gut 52 (2003) 464-470
94. Koek G.H., Sifrim D., Lerut T., et al. Effect of the GABA B agonist baclofen in patients with symptoms and duodeno-gastro-oesophageal reflux refractory to proton pump inhibitors. Gut 52 (2003) 1397-1402
95. Falk G.W., Fennerty M.B., and Rothstein R.I. AGA institute technical review on the use of endoscopic therapy for gastroesophageal reflux disease. Gastroenterology 131 (2006) 1315-1336
96. Rothstein R., Filipi C., Caca K., et al. Endoscopic full-thickness plication for the treatment of gastroesophageal reflux disease: a randomized, sham-controlled trail. Gastroenterology 131 (2006) 704-712
97. Watson D.I. Laparoscopic treatment of gastro-oesophageal reflux disease. Best Pract Res Clin Gastroenterol 18 (2004) 19-35
98. Dominitz J.A., Dire C.A., Billingsley K.G., et al. Complications and anti-reflux medication use after antireflux surgery. Clin Gastroenterol Hepatol 4 (2006) 299-305
99. Allgood P.C., and Bachmann M. Medical or surgical treatment for chronic gastroesophageal reflux? A systematic review of the published evidence of effectiveness. Eur J Surg 166 (2000) 713-721
100. Tran T., Spechler S.J., Richardson P., et al. Fundoplication and the risk of esophageal cancer in gastroesophageal reflux disease: a Veterans Affair Cohort Study. Am J Gastroenterol 100 (2005) 1002-1008
101. Lundell L., Meittiner P., Myrvold H.E., et al. Continued (5 yr) follow-up of a randomized clinical study comparing antireflux surgery and omeprazole in gastroesophageal reflux disease. J Am Coll Surg 192 (2001) 172-181
102. Hatch K.F., Daily M.F., Christiansen B.J., et al. Failed fundoplication. Am J Surgery 188 (2004) 786-791